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Abstract 
Background: Current guidelines recommend palliative care based on individual needs for patients with 
idiopathic pulmonary fibrosis (IPF). However, patients with interstitial lung disease (ILD) are less likely to 
receive specialist palliative care services compared with patients with malignant disease. The aim of this 
review is to summarise recent studies addressing barriers to referring patients to specialist palliative 
care services. Methods: PubMed, Embase, Medline and Web of Science were reviewed to identify 
relevant publications. Studies were selected if they examined the frequency of specialist palliative care 
referral and/or addressed issues surrounding access to palliative care services for patients with ILD. 
Results: Ten studies with a total of 4073 people with ILD, 27 caregivers, and 18 healthcare professionals 
were selected and analysed. Frequency of palliative care referrals ranged from 0% to 38%. Delay in 
palliative care referrals and end-of-life decisions, patients’ fear of talking about the future, prognostic 
uncertainty, and confusion about the roles of palliative care were identified as barriers to accessing 
palliative care services. Conclusion: Further research should concentrate on the early identification of 
patients who need specialist palliative care possibly with establishment of criteria to trigger referral 
ensuring that referrals are also based on patient’s needs 
Keywords: idiopathic pulmonary fibrosis, interstitial lung disease, palliative care, supportive care, end-
of-life 
Introduction  
Interstitial lung diseases (ILDs) have a significant detrimental impact on patients’ independence and 
mental well-being. Idiopathic pulmonary fibrosis (IPF), the most common form of ILD, is a life-limiting 
condition that causes 5000 deaths each year, and the incidence is increasing in the UK (1, 2). Despite 
emerging new therapies, notably pirfenidone and nintedanib, IPF remains a progressive and incurable 
disease for the majority of patients who are not suitable for lung transplantation. Management involves 
mostly supportive measures, including pulmonary rehabilitation, oxygen therapy and the treatment of 
acute exacerbations (3). The median survival length of IPF patients is 2 to 5 years, which is comparable 
with that of malignant lung diseases (4, 5). Non-IPF fibrotic ILD also carries a poor prognosis (6). New 
antifibrotic agents do not reverse existing fibrosis and there are no effective treatments for end stage 
disease.  
ILD patients report impaired quality of life secondary to poorly controlled symptoms, including 
breathlessness, coughing, sleep disturbances, and exhaustion (7). The physical symptoms frequently 
result in emotional stress, including depressed mood, fear, frustration and anger (8, 9). Compared with 
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lung cancer patients, patients with ILD have a high symptom burden with breathlessness and cough 
being the most prevalent (10, 11). 
Palliative care aims to improve patients’ quality of life by reducing suffering and supporting spiritual and 
psychological needs. Several studies have shown that specialist palliative care significantly improves 
quality of life in patients with malignant diseases and with non-cancer respiratory diseases (12, 13). In 
addition to symptomatic benefits, early integrated palliative care is associated with improved survival in 
advanced cancer patients (14). Palliative care services improve patients’ quality of life and facilitate 
better symptom management in patients with non-malignant diseases (13). Current guidelines 
recommend palliative care in conjunction with disease-focused care based on individual needs for 
patients with IPF (15, 16). However, ILD patients are less likely to receive specialist palliative care 
services compared with patients with malignant lung diseases (11). Specialist palliative care refers to the 
care provided by professionals who have undergone recognised specialist palliative care training and 
who are members of specialist palliative care team whereas generalist palliative care refers to the care 
provided by other healthcare professionals (17, 18).   
Patients’ access to a specialist palliative care team is often dependent on the physician’s judgement in 
the absence of automatic referral systems. Focusing on intervention without addressing the barriers to 
referring patients to specialist palliative care services may not be successful in improving palliative care 
access, leaving the majority of patients without access to palliative care services.  This study aimed to 
explore current evidence of the utilisation of palliative care services in the management of interstitial 
lung disease by examining (1) specialist palliative care referral rates, (2) timing of referrals and (3) 
barriers and facilitators to specialist palliative care referrals. Previous reviews have considered symptom 
prevalence and symptom control in ILD, and palliative care in non-malignant lung conditions (10, 19, 20). 
Therefore, we wished to focus on access to specialist palliative care services in management of ILD.   
Methods 
Study design  
The systematic review is registered with PROSPERO, registration number: CRD42017077494. We 
followed Cochrane methodology Version 5.1.0 (21) and PRISMA reporting standards (22). The initial 
search was conducted between August 2017 and September 2017 and an update search was conducted 
in June 2018. 
Entry criteria 
Studies were included if (1) they examined people with a labelled diagnosis of any form of interstitial 
lung disease without necessarily making any reference to diagnostic criteria (2) discussed barriers, 
facilitators or issues about accessing palliative or supportive care. Both qualitative and quantitative 
studies were considered. Studies reporting the views and behaviours of relatives of people with 
interstitial lung disease and health care professionals were considered. Review articles, conference 
abstracts, case studies, comments and editorials were excluded. Manuscripts written in non-English 
language were also excluded (Table 1). 
Search strategy 
Four electronic databases (PubMed, Embase, Medline, and Web of Science) were reviewed to identify 
relevant publications. They were chosen as they encompass the majority of the medical literature. Grey 
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literature was not searched.  Search terms included (“Lung Diseases, Interstitial”[Mesh], “interstitial lung 
disease” OR “interstitial lung diseases” OR “interstitial pneumonia” OR “interstitial pneumonias” OR 
“idiopathic pulmonary fibrosis” OR “pulmonary fibrosis” OR “fibrotic lung” OR “usual interstitial 
pneumonia”) combined with (“Palliative Care"[Mesh] OR "Terminal Care"[Mesh] OR “palliative” OR 
“palliation” OR “end of life” OR “end-of-life” OR “terminal care” OR “supportive care” OR “hospice 
care”). We screened the reference lists and citations of relevant studies to identify additional studies 
and searched for studies referencing the identified articles.     
Data collection and quality assessment  
The search results were screened independently by two reviewers (JK and CA). Any disagreement was 
resolved by a third party (AMW). Data were extracted independently by two reviewers (JK and CA) using 
a structured data extraction form. Any disagreement was resolved by discussion. Quality assessment 
was performed by two reviewers (JK and CA). The Newcastle-Ottawa scale adapted for cross-sectional 
studies was used for quality assessment of quantitative studies (23). It scores studies out of 10 by 
assessing the quality of study in three domains: selection (maximum five stars), comparability 
(maximum two stars), and outcome (maximum three stars). Qualitative studies were assessed using the 
Critical Appraisal Skills Programme (CASP) Qualitative Checklist (24). It entails 10 questions 
encompassing topics of validity, results, and value of study.  
Results 
Characteristics of the studies 
The search identified 645 publications with 37 full text articles reviewed. Of 37, ten studies were 
selected (figure 1). Of these, eight studies involved ILD patients or caregivers of ILD patients. Two studies 
not specific to ILD population were also included as they included people with ILD (25, 26). Two studies 
were qualitative, and the remaining studies were quantitative. In this review, narrative analysis was 
used given the heterogeneity of the included studies. Table 2 describes the characteristics of the 
included studies. Most the studies were based in the USA or in Scandinavia with one study evaluating 
carers and healthcare professionals from Northern Ireland. 
Quality assessment 
Convenience sampling was used in both of the qualitative studies, therefore there may have been a 
selection bias. Data were analysed using thematic analysis of semi-structured interviews and focus 
groups. In both studies, there was no discussion whether number of focus groups and interviews were 
sufficient to reach data saturation. 
The quality of the eight quantitative studies ranged from four to six stars (Table 3). All eight studies were 
retrospective in nature, with the potential for record bias.  The majority of the studies were of a small 
sample size although two studies reviewed large databases; the sample size ranged from 13 to 3166 
people. Three of the studies including people in an intensive care setting and are therefore not likely to 
be generalizable to the ILD community as a whole. Five studies defined the provision of palliative care 
based on database records. However only one of those studies reported the validity of those database 
records (11). Three studies did not report the prevalence of any comorbidities,(11, 27, 28) and one study 
reported the prevalence of cancer but no other comorbidities (29). Five studies involved data from deceased 
IPF or ILD patients. However, only one of these studies examined the cause of death (30).   
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Referral rates 
The frequency of specialist palliative referrals ranged from 0% to 38% (26, 27, 29-32). Bajwah et al. 
reported that of 38% of patients received palliative care input, only four (9%) had access to both 
hospital and community palliative care services (31). Two studies explored palliative care access for ILD 
patients compared with lung cancer patients (11, 28). In both studies, there was no statistically 
significant difference in specialist palliative care referral rate for consultation between ILD patients and 
lung cancer patients.  
Timing of referral  
One study described a correlation between the time of palliative care referral and the time of death 
(r=0.99; p<0.001) (27). In this study, only 13.7% of patients received referrals, and 71% of these referrals 
were made in the last month of life, suggesting that the referrals are late in the disease course.  
Rajala et al. described significant delays in end-of-life care decisions; with 32% having documented end-
of-life decisions (30). A total of 74% of end-of-life decisions were made in the last 3 days of life. Life-
prolonging treatments such as antibiotics (66%) or non-invasive ventilation (29%) were frequent during 
the last week of life, and 25 (42%) patients had laboratory tests during the last 24 hours of life (30).  
Deaths of ILD patients were more likely to be ‘unexpected’ compared with lung cancer patients (15% vs. 
4%, p<0.001) and end-of-life discussions with patients and their families were less likely to occur (41% 
vs. 59%, p<0.001 and 52% vs. 73%, p<0.001) (11).  
Barriers 
Hesitancy to engage in palliative care due to fear of talking about the future, the wish to focus on 
positive aspects, prognostic uncertainty, and confusion about the roles of palliative care were observed 
as barriers (25, 33). Palliative care referrals were negatively associated with Hispanic race in a US 
database review (29).  
Facilitators 
Patients who received palliative care team input had more ILD specialist centre visits than patients who 
did not (27). The author suggested that patients who had more clinic visits had more opportunities to 
establish rapport with health care professionals, facilitating the discussion of palliative care options and 
subsequent arrangement of a formal palliative care referral. Older age, urban teaching hospital settings, 
and “do not resuscitate” (DNR) status were associated with increased palliative care access for patients 
with IPF undergoing mechanical ventilation in the USA (29). 
Discussion and future perspectives  
Reviewing the available literature on palliative care for ILD confirmed a low percentage referral to 
specialist palliative care services and also a late referral with many people being referred in the late 
stage of their disease. Our review identified that the main barriers to referral to palliative care included 
attitudes to palliative care from both patients and healthcare practitioners, difficulty estimating 
prognosis, as well as circumstantial factors. Despite thorough searching, our findings are based on 
limited data as we only identified ten papers. This highlights the research need in this area given the 
importance of ensuring people with ILD have appropriate access to specialist palliative care services. 
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The low referral rate data presented in this review are in keeping with the findings of the British 
Thoracic Society interstitial lung disease registry, which previously demonstrated that only half of 
centres assessed palliative care needs at each clinic visit, and that only 3% of patients referred at first 
visit (34). Low referral rates and late referrals to specialist palliative care team have been observed in 
the management of COPD patients compared with people with heart failure, severe dementia or cancer 
(35). A literature review of qualitative studies on different chronic conditions described that most 
people with advanced lung diseases did not perceive their condition as life-threatening (36). From our 
search, there are no published data reporting specialist palliative care referral patterns for ILD patients 
compared with people with other non-malignant chronic conditions. A further study on this topic may 
help us to understand unknown barriers.  
The death of people with ILD were more likely to be “unexpected” compared to those with cancer and, 
concurrent life-prolonging treatment and end-of-life treatment was frequent, suggesting physician’s 
potential struggle in identifying patient reaching the end of life (30). Previous studies have reported that 
prognostication difficulties due to unpredictable disease trajectory form a barrier to providing adequate 
specialist palliative care services to patients with non-malignant conditions (37). One qualitative study 
described how health care professionals have difficulties in deciding the optimal time to make specialist 
palliative care referrals when the prognosis is uncertain (25). In contrast with other chronic respiratory 
conditions such as COPD, bronchiectasis and asthma, which have an episodic pattern with exacerbations 
and frequent near full recovery, people with ILD and in particular IPF have more of a steady prognosis 
and rarely recover from exacerbations. It is therefore surprising that we identified difficulty in estimating 
prognosis to be a key barrier for ILD patients. 
Improving accuracy of prognostication may improve confidence of physicians in deciding to refer to 
palliative services, as well as allowing patients and families to plan for the future (38). However, 
palliative services should be provided based on patients’ needs rather than an arbitrary estimated life 
expectancy (39). Physician decision aids such as the Need Assessment Tool: Interstitial Lung Disease 
(NAT-ILD) (40) may be helpful. However, even with the NAT-ILD, time constraints and inadequate skills 
for exploring non-medical aspects have been shown to be barriers to palliative care referral. Automatic 
referral systems based on pre-defined criteria have been proposed for cancer patients (41, 42). Such 
systems could be adopted for ILD patients, and, for example, commencing long-term oxygen therapy 
(LTOT), or other criteria to trigger referral could be established. Standardised criteria can regulate access 
to specialist palliative care. Robust studies have been conducted and implemented in oncology and 
further research might adopt successful strategies performed in other specialties.  
Our review highlighted the poor understanding of the roles of palliative medicine by patients and 
healthcare professionals. Despite increasingly integrated palliative care services, patients’ perceptions of 
palliative care have not changed considerably (43). There is a common misconception that palliative care 
is equivalent to end-of-life care. This misconception has led to negative perceptions of palliative care 
associating it with the loss of hope and dying. Patients receiving life-prolonging or curative treatment 
fear that they may be abandoned by physicians if they require palliative care (44). This fear is not limited 
to patients. Physicians also fear that the introduction of palliative care may destroy patients’ hope (44). 
Barriers observed when providing palliative care for lung transplant candidates reflects a misconception 
and poor understanding of the roles of palliative medicine (44). Palliative care referrals should be based 
on patients’ needs, and lung transplant candidates should not be disadvantaged in their access to 
palliative care services, as transplant candidates also have palliative care needs (45). 
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The physician’s understanding of palliative medicine could be enhanced by expanding collaboration 
between ILD specialists and specialist palliative care teams via joint clinics, MDT meetings, and 
educational meetings. In addition to the gap in understanding of the roles of palliative care, one 
qualitative study identified that there were issues surrounding inadequate knowledge and experience in 
the management of ILD patients among non-ILD specialists including specialist palliative care team (46). 
This reflects the necessity to provide additional support to both respiratory and palliative care teams in 
the decision making and management of ILD patients. Additionally, increasing exposure to palliative 
medicine in medical school can introduce the importance of integrated palliative care to medical 
students at an early stage of their career (47).  
Urban teaching hospitals setting was associated with better palliative care services (48). Teaching 
hospitals are likely to have an established integrated palliative care system and higher availability of 
specialist palliative care services (49). Further studies are needed to achieve equity of access to 
specialist palliative care and adequate care transfer between different clinical settings for people with 
ILD.  
Limitations 
The main limitation of this review is that the included studies were performed in different settings, 
limiting accurate comparison of the studies. The review is based on a small number of studies and all 
quantitative studies were retrospective in nature. Additionally, we included studies of people with a 
concomitant significant medical condition and also studies that evaluated people with non-ILD respiratory 
conditions to maximise the potential of identifying possible barriers and facilitators. These alternative 
diagnoses may have influenced the patient's management plan, including specialist palliative care referrals 
and end-of-life decisions and a careful approach needs to be taken when interpreting our results. This review 
was limited to published scientific articles and we did not attempt to evaluate the grey literature and 
conference abstracts or seek data from unpublished sources because they had not undergone adequate 
peer review but we may have missed some additional barriers or facilitators. Furthermore, we did not 
include studies written in non-English language also potentially limiting the findings. We did not employ 
a librarian to generate the search terms, however we used a broad range of terms and did not identify 
papers in forward or backward searching so we believe our searching was complete.  
Conclusions  
This review has highlighted the low referral rates of people with ILD to palliative care. We identified that 
the main barriers to referral to palliative care were fear of talking about future, patients’ wish to focus 
on the positive, unpredictable disease trajectory, and poor understanding of the roles of specialist 
palliative care. The main facilitators were more contact with healthcare professionals, teaching hospital 
settings, older age, and advanced care planning. Further research should therefore concentrate on the 
early identification of patients who need specialist palliative care possibly with establishment of criteria 
to trigger referral ensuring that referrals are also based on patient’s needs. Additionally, further 
education on the roles of specialist palliative care is required to inform patients and physicians about 
the purpose of specialist palliative care referral so that it is not associated with a sense of abandonment 
or loss of hope. 
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Inclusion criteria  
Participants   Studies of adult participants with interstitial lung disease  
 Studies of participants who are family caregivers and/or 
healthcare professionals caring for patients with interstitial 
lung disease    
Outcomes   Any outcomes which reports issues surrounding access to 
specialist palliative care services, including referral rates, 
timing of referrals and barriers and facilitators to referring 
patients  
Study designs    Both quantitative and qualitative studies    
Publication types   Full texts and English language  
Exclusion criteria  
Conference abstracts, review articles, comments, and editorials   
Studies written in non-English language 
  
Table 1Inclusion and exclusion criteria
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Author, 
Year 
Aim Sample Design Method Key finding of the study  
McVeigh, 
2018(25) 
To explore generalist and specialist 
palliative care for people with non-
malignant lung diseases.  
Bereaved carers 
n=17; Health care 
professionals n=18 
(Northern Ireland) 
Qualitative Semi-structured 
interview and 
focus group  
 Barriers: poor understanding of the roles of palliative care from healthcare 
professionals and prognostic uncertainty 
 Variations in generalist and specialist palliative care provision 
Rush, 
2017(29) 
To explore palliative care access for IPF 
patients undergoing mechanical 
ventilation compared with lung cancer 
IPF n=3166 
(USA) 
Quantitative  Retrospective 
analysis of 
database 
 408 (12.9%) had a palliative care input 
 Older age, urban teaching hospital settings, DNR status and West and Midwest 
areas were associated with increased palliative care access 
 Factors associated with less PC access: Hispanic race and missing race were 
associated with less PC referrals compared with white race 
 Significant increase in number of PC referrals from 2006 to 2012   
Lindell, 
2017(33) 
To understand the palliative care 
needs in IPF patients and their 
caregivers  
IPF patients n=5 
Family caregivers n=5; 
Family caregivers of 
deceased IPF patients 
n=3 (Pittsburgh, USA) 
Qualitative  Thematic analysis 
of focus group 
 There is a high symptom burden (psychological and physical) for both patients and 
caregivers 
 Hesitancy to engage in palliative care due to fear of talking about future, wish to 
focus on the positive, confusion about roles of palliative care   
Liang, 
2017(32) 
To examine frequency and timing of 
palliative care referral in IPF patients 
admitted to ICU 
IPF n=106 
(USA) 
Quantitative Retrospective 
review of 
patients’ medical 
records 
 84% of ICU admission were due to acute respiratory deterioration.  
 27 (25%) patients received a formal palliative care referral. Of 27, four referrals 
made prior to ICU admission.  
 82 (77%) patients died in ICU 
Ahmadi, 
2016(11) 
To examine end-of-life care and 
symptom prevalence in oxygen-
dependent fibrotic-interstitial lung 
disease compared with lung cancer 
patients.  
ILD n=285 
Lung cancer 
n=10,822 
(Sweden) 
Quantitative  Retrospective 
analysis of the 
database 
 Death of ILD patients were more likely to be ‘unexpected’ (15% vs. 4%, p<0.001). 
EOL discussion with patients and their families were less likely to occur (41% vs. 
59%, p<0.001 and 52% vs. 73%, p<0.001). 
 The difference in palliative care team consultation between IPF and lung cancer 
patients was not statistically significant (6% vs. 19%, p=0.655). 
 An infrequent usage of validated symptom scale for pain and other symptoms (13% 
vs. 28%, p<0.001 and 8% vs. 14%, p=0.004, respectively) in ILD patients  
 IPF patients were more likely to have unrelieved breathlessness, pain and anxiety 
Rajala, 
2016(30) 
To examine end of life care in patients 
with IPF 
Deceased IPF 
patients n=59 
(Finland) 
Quantitative Retrospective 
healthcare 
documentation 
review   
 No documented specialist palliative care was identified. Only 1 patient was referred 
to a hospice 
 Concurrent life-prolonging treatment and EOL treatment 
 19 (32%) had documented EOL decisions. 74% of EOL decisions were made in the 
last 3 days of life  
Brown, 
2016(28) 
To explore palliative care for patients 
with ILD and COPD who die in 
intensive care unit compared with lung 
cancer  
ILD n=79; COPD 
n=592; Lung cancer 
n=158 
(Seattle, USA) 
Quantitative  Retrospective 
review of 
patients’ medical 
records 
 No statistical difference in palliative care consultation (OR 0.87, 95% CI 0.33-2.28, 
p=0.771). 
 An inadequate documented pain assessment (OR 0.43, 95% CI 0.19-0.97, p=0.043) 
in the last 24 hours of life.  
 DNR order and documented discussion of prognosis were less likely to occur (OR 
0.40, 95% CI 0.19-0.86 and OR 0.36, 95% CI 0.19-0.66, respectively) compared with 
cancer patients  
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Lindell, 
2015(27) 
To investigate timing of palliative care 
referrals in patients with IPF  
Total n=404 
Known location of 
death n=277; 
unknown location of 
death n=127 
(Pittsburgh, USA) 
Quantitative  Retrospective 
analysis of a 
clinical database 
 13.7% of patients who died in hospital received a formal palliative care 
consultation. 
 A correlation between the time of PC referral and the time of death (r=0.99, 
p<0.001), indicating that palliative input occurred close to time of death.  
 Deceased people who received palliative care team input had more ILD specialist 
centre visits (mean: 8.0 visits [SD±6.1]) than patients who did not (mean: 5.2 visits 
[SD±5.4]). 
 Patients seen by palliative care were more likely to die in an academic medical 
centre or hospice. 
Colman, 
2015(26) 
To investigate outcome of lung 
transplant candidate referred to 
palliative care services   
Total n=308 
People referred to 
palliative care n=64 
(Ontario, Canada) 
Quantitative  Retrospective 
analysis of 
healthcare 
records 
 64 (20.7%) was referred to palliative care services 
 Of 64,51 (80%) had a diagnosis of ILD 
 The median timing of palliative care referral from transplant listing was 65 days. 
The median timing of referral from delisting or death was 32 days.  
Bajwah, 
2012(31) 
To understand the palliative care and 
end-of-life planning needs in patients 
with fibrotic ILD  
ILD n=45 
(London, UK) 
Quantitative Retrospective 
review of 
patients’ records  
 17 (38%) had specialist palliative care input. 4(9%) had both hospital and 
community palliative care. 28 patients (62%) did not have any palliative care input 
in their last year of life. 
 Few patients had a preferred place of care (8/45) or place of death (6/45) 
 34 (76%) patients died in the hospital. 
Table 2 Characteristics of the Included Studies 
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First 
Author, 
Year 
Selection of participants  Confounding measurement  Outcome measurement  
Rush, 
2017(29) 
 ★ ★ ☆ ☆ ☆ 
IPF patients undergoing mechanical ventilation.  
 
 ★ ☆ 
No comorbidities recorded other than malignancy  
Cause of death not recorded  
 ★ ★ ★ 
Sensitivity and specificity of palliative care codes are unknown in patients 
with IPF (coding error) 
Liang, 
2017(32) 
★ ★ ☆ ☆ ☆ 
IPF patients who was admitted to an ICU. Single centre 
study 
★ ☆ 
Reasons for hospital and ICU admission explored.  
★ ★ ★ 
Outcome collected retrospectively. Palliative care defined as 
documented evidence a formal consultation.  
Ahmadi, 
2016(11) 
 ★ ★ ☆ ☆ ☆ 
Only oxygen dependent ILD patients, may represent 
more severe disease only 
Of 490 deceased people with IPF, 205 patients were 
excluded as data missing from the SPRC registry 
 
 ☆ ☆ 
No comorbidities recorded  
 ★ ★ ★ 
SPRC collect data retrospectively after patients’ deaths (recall bias) 
No statistically significant difference in specialist palliative consultations. 
However, ILD population (n=285) was significantly smaller than the 
population of lung cancer (n=10,822). Therefore, it seems possible that 
these results are due to small sample size of the ILD group. 
Rajala, 
2016(30) 
 ★ ★ ★ ☆ ☆ 
Includes all patients recruited to a prospective, national 
clinical registry (2012 to February 2014). Unclear if 
national registry collects all patient diagnosed with IPF. 
Likely representative but small sample size. 
 
 ☆ ☆ 
Comorbidities recorded. 17% of study population had 
cancer. Cause of death was IPF in 42 (71%) of patients. 
29% died of other causes including cancer (10%) and 
cardiovascular disease (12%) 
 ★ ★ ☆ 
Access to individual notes of all patients in registry available as well as 
death certificates. Outcomes collected retrospectively and required 
accurate records. 
Brown, 
2016(28) 
 ★ ★  ☆ ☆ ☆ 
IPF patients who died in intensive care unit only. Small 
ILD sample size  
 ★ ☆ 
Reasons for hospital and ICU admission not explored  
Comorbidities not recorded but excluded patients with 
more than one of COPD, ILD, or lung cancer 
 ★ ★ ★ 
No statistically significant difference in specialist palliative care 
consultations. However, ILD population (n=79) was smaller than the 
population of lung cancer (n=158) 
 
Lindell, 
2015(27) 
 ★ ★ ☆ ☆ ☆ 
 Exclusion of patients where place of death unknown 
may affect generalization to all IPF patients 
Single centre study  
 
 ☆ ☆ 
No comorbidities recorded 
Cause of death not recorded  
 ★ ★ ★ 
Death notifications within an 18-hospital network allowed location of 
significant number of deaths to be identified. Palliative care input defined 
as a dictated palliative-care consultation. 
Colman, 
2015(26) 
★ ★ ☆ ☆ ☆  
Included candidates for lung transplant from multiple 
respiratory conditions. Includes ILD patients but does 
not specify whether IPF or alternative diagnosis. 
ILD responsible for majority of palliative care referrals 
(51 patients; 80%). 
Single centre study 
 ☆ ☆  
No specific analysis of ILD (or subgroups) 
Comorbidities only recorded for people referred to 
palliative care 
★ ★ ★  
Assessment of the outcomes not described – data extracted by 
appropriately trained member of the team. 
Appropriate statistical methods employed 
11   
 
   
 
Table 3 Quality assessment of included studies 
Bajwah, 
2012(31) 
 ★ ★  ☆ ☆ ☆ 
Two large London (UK) tertiary centres with 
demographic variation (cultural and socioeconomic)  
Small sample size  
 ☆ ☆ 
Comorbidities recorded but not controlled 
Cause of death not recorded  
 ★ ★ ☆ 
Pre-specified data-extraction sheet collected outcomes from individual 
patient note sets. Data collected retrospectively. 
Qualitative study  
McVeigh, 
2018(25) 
Not specific to IPF population (ILD cause of death for 4 
out of 17 bereaved carers). 
Included health care professionals and care givers, taken 
from 2 sites (1 rural, 1 urban) each in Republic of Ireland 
and Northern Ireland. 
More health-care professionals (18) than care givers (17) 
Specific IPF/ILD carers not identified in results 
Semi-structured interviews with carers. Focus groups undertaken with 
health care professionals. All data were audio-recorded and then 
transcribed, analysed using thematic analysis switch coding software used 
to aid analysis. 
Lindell, 
2017(33) 
May not representative of general IPF population – 
convenience sampling (selection bias)  
Single centre study  
More care-givers (8) than patients (5) Audio recording of focus groups; appropriate size (3-5 participants per 
group). Coding software used to identify major concepts/themes, multiple 
coders used to identify themes. No discussion of whether number of focus 
groups was sufficient to identify all themes (saturation). 
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